KABIVEN G 11% 1920mL injection bag Australia - English - Department of Health (Therapeutic Goods Administration)

kabiven g 11% 1920ml injection bag

fresenius kabi australia pty ltd - soya oil, quantity: 200 mg/ml - injection, emulsion - excipient ingredients: sodium hydroxide; egg lecithin; glycerol; water for injections - parenteral nutrition for patients when oral or enteral nutrition is impossible or insufficient or contraindicated.

StructoKabiven Singapore - English - HSA (Health Sciences Authority)

structokabiven

fresenius kabi (singapore) pte ltd - (amino acid solution) calcium chloride dihydrate corresp. to calcium chloride 0.56g; (amino acid solution) glycine (aminoacetic acid); (amino acid solution) l- histidine; (amino acid solution) l- isoleucine; (amino acid solution) l- leucine; (amino acid solution) l- methionine; (amino acid solution) l- serine; (amino acid solution) l- threonine; (amino acid solution) l- valine; (amino acid solution) l-alanine; (amino acid solution) l-arginine; (amino acid solution) l-lysine acetate corresp. to l-lysine 6.6g - emulsion - 0.740g per 1000ml - (amino acid solution) calcium chloride dihydrate corresp. to calcium chloride 0.56g 0.740g per 1000ml; (amino acid solution) glycine (aminoacetic acid) 11.0g per 1000ml; (amino acid solution) l- histidine 3.0g per 1000ml; (amino acid solution) l- isoleucine 5.0g per 1000ml; (amino acid solution) l- leucine 7.4g per 1000ml; (amino acid solution) l- methionine 4.3g per 1000ml; (amino acid solution) l- serine 6.5g per 1000ml; (amino acid solution) l- threonine 4.4g per 1000ml; (amino acid solution) l- valine 6.2g per 1000ml; (amino acid solution) l-alanine 14.0g per 1000ml; (amino acid solution) l-arginine 12.0g per 1000ml; (amino acid solution) l-lysine acetate corresp. to l-lysine 6.6g 9.3g per 1000ml; (amino acid solution) l-phenylalanine 5.1g per 1000ml; (amino acid solution) l-proline 11.2g per 1000ml; (amino acid solution) l-tryptophan 2.0g per 1000ml; (amino acid solution) l-tyrosine 0.40g per 1000ml; (amino acid solution) magnesium sulphate heptahydrate corresp. to magnesium sulphate 1.2g 2.47g per 1000m

BIOLOGICAL THERAPIES DISODIUM EDETATE 3g + SODIUM ASCORBATE 5g 50mL injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

biological therapies disodium edetate 3g + sodium ascorbate 5g 50ml injection vial

orthomolecular medisearch laboratories pty ltd trading as biological therapies - sodium ascorbate, quantity: 100 mg/ml; disodium edetate, quantity: 60 mg/ml - injection, concentrated - excipient ingredients: water for injections; sodium hydroxide - 1. disodium edetate is particularly effective in treating lead accumulation and lead poisoning. this is especially so where there is a concomitant hypercalcaemic problem (refer "indications (2)"). however it must be noted that disodium edetate is equally effective with calcium disodium edetate in removing heavy metals, even in the absence of hypercalcaemia. for patients with elevated serum calcium or hypermobility of their body pools of calcium where there may be transiently or prolonged raised serum calcium (see "indications (2)"), the edta of choice for removing heavy metals may be disodium edetate. there are no recognised safe limits for lead intoxication. lead poisoning may occur by ingestion or inhalation of lead dust or fumes. poisoning is manifested by a metallic taste, anorexia, irritability, apathy, abdominal colic, vomiting, diarrhoea, constipation, headache, leg cramps, black stools, oliguria, stupor, convulsions, palsies and coma. chronic lead poisoning causes variable involvement of the central n

BIOLOGICAL THERAPIES DISODIUM EDETATE SOLUTION 3g/100mL injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

biological therapies disodium edetate solution 3g/100ml injection vial

orthomolecular medisearch laboratories pty ltd trading as biological therapies - disodium edetate, quantity: 30 mg/ml - injection, concentrated - excipient ingredients: water for injections - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code) 1. disodium edetate is particularly effective in treating lead accumulation and lead poisoning. this is especially so where there is a concomitant hypercalcaemic problem (refer "indications (2)"). however it must be noted that disodium edetate is equally effective with calcium disodium edetate in removing heavy metals, even in the absence of hypercalcaemia. for patients with elevated serum calcium or hypermobility of their body pools of calcium where there may be transiently or prolonged raised serum calcium (see "indications (2)"), the edta of choice for removing heavy metals may be disodium edetate. there are no recognised safe limits for lead intoxication. lead poisoning may occur by ingestion or inhalation of lead dust or fumes. poisoning is manifested by a metallic taste, anorexia, irritability, apathy, abdominal colic, vomiting, diarrhoea, cons

SYNTHAMIN 17 10% Amino Acid without Electrolytes 500mL injection bottle AHA6920 Australia - English - Department of Health (Therapeutic Goods Administration)

synthamin 17 10% amino acid without electrolytes 500ml injection bottle aha6920

baxter healthcare pty ltd - leucine, quantity: 7.3 g/l; phenylalanine, quantity: 5.6 g/l; methionine, quantity: 4 g/l; lysine hydrochloride, quantity: 7.24 g/l (equivalent: lysine, qty 5.8 g/l); isoleucine, quantity: 6 g/l; valine, quantity: 5.8 g/l; histidine, quantity: 4.8 g/l; threonine, quantity: 4.2 g/l; tryptophan, quantity: 1.8 g/l; alanine, quantity: 20.7 g/l; glycine, quantity: 10.3 g/l; arginine, quantity: 11.5 g/l; proline, quantity: 6.8 g/l; tyrosine, quantity: 400 mg/l; serine, quantity: 5 g/l - injection, intravenous infusion - excipient ingredients: sodium metabisulfite; glacial acetic acid; water for injections - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)

ACIDIC BICARBONATE HAEMODIALYSIS CONCENTRATE SW127A Zimbabwe - English - Medicines Control Authority

acidic bicarbonate haemodialysis concentrate sw127a

b. braun medical (pty) ltd - calcium chloride dihydrate; glacial acetic chloride; glucose monohydrate; magnesium chloride hexahydrate; potassium chloride; sodium chloride - solution - 3.558; 5.219; 6.305; 6.432; 38.5; 210.678g

ACIDIC BICARBONATE HAEMODIALYSIS CONCENTRATE SW139A Zimbabwe - English - Medicines Control Authority

acidic bicarbonate haemodialysis concentrate sw139a

b. braun medical (pty) ltd - calcium chloride dihydrate; glacial acetic chloride; glucose monohydrate; magnesium chloride hexahydrate; potassium chloride; sodium chloride - solution - 3.558; 5.219; 6.305; 9.010; 38.5; 210.678g

ACIDIC BICARBONATE HAEMODIALYSIS CONCENTRATE SW380A Zimbabwe - English - Medicines Control Authority

acidic bicarbonate haemodialysis concentrate sw380a

b. braun medical (pty) ltd - calcium chloride dihydrate; glacial acetic chloride; glucose monohydrate; magnesium chloride hexahydrate; potassium chloride; sodium chloride - solution - 3.558; 5.219; 6.305; 7.719; 38.5; 210.678g

REN-ACID SK-F 213 DIALYSATE South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

ren-acid sk-f 213 dialysate

fresenius kabi south africa (pty) ltd - dialysate - see ingredients - each 1000,0 ml solution contains calcium chloride 9,004 g dextrose monohydrate equivalent to dextrose 175,0 g glacial acetic acid 6,311 g glucose 38,5 g magnesium chloride 3,558 g potassium chloride 5,222 g sodium

REN-ACID SK-F 219 LOW CA/GLUCOSE DIALYSATE South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

ren-acid sk-f 219 low ca/glucose dialysate

fresenius medical care south africa (pty) ltd - dialysate - see ingredients - each 1000,0 ml solution contains calcium chloride 6,431 g dextrose monohydrate equivalent to dextrose 175,0 g glacial acetic acid 6,311 g glucose 38,5 g magnesium chloride 3,558 g potassium chloride 5,222 g sodium